The use of whole-body kinematic technology for optimizing current steering deep brain stimulation in Parkinson’s disease patients

Patients with advanced Parkinson’s disease (PD) may develop motor complications caused by Levodopa, the current drug used for treatment. Deep brain stimulation (DBS) is an alternative surgical treatment where electrodes are implanted in a specific brain region to deliver current to surrounding brain tissue which helps to alleviate motor symptoms of PD. Presently, there is […]

Read More
Characterization of cell signaling in response to ultraviolet radiation after treatment with an oral skin-care supplement

Bend Beauty is a Halifax based company involved in the research, development, and marketing of oral natural health products for use in skin-care and anti-aging. Bend?s core product, Anti-Aging Formula, is a mixture of the active ingredients fish oil, borage oil, lutein, zeaxanthin, and vitamin D3. An eight-week human clinical study demonstrated this product increases […]

Read More
Modulation of human induced pluripotent stem cell-derived cardiomyocyte (hiPSC-CM) ion channels and transporter activity, measured by atomic absorption spectroscopy (AAS)

During human clinical trials, a large percentage of candidate drugs fail because they are unsafe or ineffective. Even when preclinical cell and animal studies seem positive, problems occur because drugs tested with these models are often not predictive of what happens in humans. Many drugs, including non-cardiovascular drugs, target ion channels of the heart (membrane […]

Read More
Designing quality control strategies to assess the self-assembly and biological stability of chitosan nanoparticles

In this grant, the consortium will develop new methods to characterize nanoparticles prepared with a proprietary polymer. This study will enable the fabrication and characterization of better performing nano-sized particles encapsulating therapeutic molecules, commonly called nanomedicines. This study will allow to monitor how the polymers self-assemble into nanoobjects under different conditions, and to study how […]

Read More
Exploring medical potential of cannabinoids

Evaluating the medicinal use of cannabinoids represents an area of massive untapped potential, especially considering its upcoming legalization in Canada. Currently, a significant proportion of medical cannabis research is based on self-reported use and outcomes, rather than carefully-designed research studies. Here, we aim to better understand the impact of cannabis administration in adults with obesity […]

Read More
Scientific and Clinical Hub for Orphan Drug Development

With rapid and cost-effective genome sequencing becoming the norm, many causal mutations for inherited genetic diseases are being rapidly determined. The discovery of new genes for inherited diseases is enabling rapid genetic and chemical genetic platforms to be used to discover drug targets and drugs/drug-like molecules as potential treatment options for patients with inherited diseases. […]

Read More
Development and validation of BRET-based biosensors for drug candidate profiling

G protein coupled receptors (GCPRs) are proteins found at the surface of cells are responsible for activating numerous intracellular signaling pathways and thus are involved in regulating about every physiological response. Activation of GPCRs occurs by compounds as varied as photons, lipids, ions, small hormonal or neurotransmitter compounds or larger peptidic and protein molecules. As […]

Read More
Chitosan-derivatives as a platform for drug and protein delivery

Triozan™ is a safe, biodegradable and biocompatible hydrophilic and highly quaternized biopolymer with advantageous physicochemical properties that enables an efficient encapsulation and protection of drug molecules against degradation while simultaneously maintaining therapeutic integrity. We propose to encapsulate three drug candidates into nanogels formed from Triozan to enhance their therapeutic application and overcome multiple barriers such […]

Read More
Elaboration of a Phase II clinical study protocol for the treatment of metastatic non-small cell lung cancer (NSCLC) using AB-16B5, an epithelial to mesenchymal transition (EMT) inhibitor, in combination with docetaxel

The molecular mechanisms responsible for the occurrence of metastatic cancer are beginning to be elucidated with the identification of key regulators. Increasing evidence points to tumor cell epithelial to mesenchymal transition (EMT) as an important contributing process to metastatic evolution. The identification of factors that are stimulated during EMT might provide the means to develop […]

Read More
Assessment of DNA Ministring technology in cell transfection and the treatment of Colorectal Cancer (CRC)

Despite the power of gene therapy, its successful application to medicine has been diminished due to: (i) high toxicities and potentially fatal adverse effects; (ii) poor transgene expression in target cells; and (iii) extensive vector degradation. While viral vectors greatly improve efficiency, they sometimes lead to cancers due to chromosomal integration and may suffer from […]

Read More